Investigator’s gender and clinical trials performance in recruitment of patients
DOI:
https://doi.org/10.18203/2349-3259.ijct20230057Keywords:
Gender, Clinical trials, RecruitmentAbstract
Mostly of attraction to gender is related with participant subjects of clinical trials. Based on percentage of subject of each gender it is calculating enrollment fracture, bias and some other indexes. Enrollment is very important parameter and genders is considering as one of the internal factors which is influencing to enrollment. Authors also marking the more prevalence of male above the female in some aspects of clinical trials. It is obviously that investigators also has a differences in gender and this could have a differences in some parameters and enrollment is one of them. Enrolment parameters also not developed very much. We stepped forward to find out the relations of gender’s investigator and the enrollment. Materials and methods: Data of four clinical trials II-III phases in oncology and hematology, conducted since 2007 to 2017 years has been used for retrospective analysis. Study objectives: to investigate the study recruitment rate using different parameters and it’s changes along with acting of gender’s of investigator; to develop new parameters and values (derivatives) which could be sensitive for evaluation of enrollment. Statistical analysis: data had been collected from feasibility questionnaires, open statistical sources. Results: It was showed the values of enrollment parameters in perspective of investigator’s gender. Discussion: Statistical differences in some existing and developed enrollment parameters has been found. Gender’s influence to enrollment also was investigated.
References
Committee on the ethical and legal issues relating to the inclusion of women in clinical studies: women and health research: ethical and legal issues of including women in clinical studies. Washington: National Academy Press; 1994.
NIH guide for grants and contracts. Available at: https://grants.nih.gov/funding/about-nih-guide-to-grants-and-contracts. Accessed on 20 December 2021.
Meinert C, Gilpin AK, Unalp A, Dawson C. Gender representation in trials. R Control Clin Trials. 2000; 21:462-75.
Meinert CL, Gilpin AK. Estimation of gender bias in clinical trials. Stat Med. 2001;20(8):1153-64.
Chin Feman SP, Nguyen LT, Quilty MT, Kerr CE, Nam BH, Conboy LA, Singer JP, Park M, Lembo AJ, Kaptchuk TJ, Davis RB. Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. Contemp Clin Trials. 2008;29(2):241-51.
Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156-164.
van den Bor RM, Grobbee DE, Oosterman BJ, Vaessen PWJ, Roes KCB. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemp Clin Trials Commun. 2017;7:208-216.
Kibby M. Feasibility of patient recruitment into clinical trials of experimental treatments for acute spinal cord injury. J Clin Neurosci. 2012;19(10): 1338-43.
Fouad MN, Lee JY, Catalano PJ, Vogt TM, Zafar SY, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CI. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013;9(2):e40-7.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race, sex and age-based disparities. JAMA. 2004;291:2720-6.
Stewart JH, Bertoni AG, Staten JL. Participation in surgical oncology clinical trials: Gender, race/ethnicity, and age-based disparities. Ann Surg Oncol. 2007;14:3328-34.
Du W, Gadgeel SM, Simon MS. Predictors of enrollment in lung cancer clinical trials. Cancer. 2006;106:420-5.
Nass SJ, Moses HL, Mendelsohjn J. A national cancer clinical trials system for the 21st century. Washington DC: National Academies Press; 2010.
Hill NS, Preston IR, Roberts KE. Patients with pulmonary arterial hypertension in clinical trials Who are they?. Proc Am Thorac Soc. 2008;5:603-9.
Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess. 1999;3:1-143
Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. Trials. 2012;13:218
Taylor RW, Zimmerman JL, Dellenger RP, Straube RC, Criner GJ, Davis K, et al. Small, Inhaled nitric oxide in ARDS study group. Lowdose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. J Am Med Assoc. 2004;291:1603-9.